INSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Expand Collaboration to Include Clinical Study of Cannabidiol in Early Psychosis
pharmaceutical-investing FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Epinephrine Nasal Spray as Investigational Treatment for Anaphylaxis
pharmaceutical-investing INSYS Therapeutics Reaches Agreement in Principle to Settle Department of Justice Investigation
